Advaxis (ADXS) 10-Q 14 Jun 21 2021 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Apr. 30, 2021	Jun. 07, 2021
Cover [Abstract]
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	0001100397
Document Type	10-Q
Document Period End Date	Apr. 30, 2021
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		145,638,459
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Apr. 30, 2021	Oct. 31, 2020
Current Assets:
Cash and cash equivalents	$ 48,110	$ 25,178
Deferred expenses	1,333	1,808
Accounts receivable	1,375
Prepaid expenses and other current assets	1,295	865
Total current assets	52,113	27,851
Property and equipment (net of accumulated depreciation)	333	2,393
Intangible assets (net of accumulated amortization)	3,325	3,261
Operating right-of-use asset (net of accumulated amortization)		4,839
Other assets		182
Total assets	55,771	38,526
Current liabilities:
Accounts payable	1,156	410
Accrued expenses	2,133	1,737
Common stock warrant liability	4,931	17
Current portion of operating lease liability		962
Deferred revenue		165
Total current liabilities	8,220	3,291
Operating lease liability, net of current portion		5,055
Total liabilities	8,220	8,346
Commitments and contingencies - Note 9
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at April 30, 2021 and October 31, 2020; Liquidation preference of $0 at April 30, 2021 and October 31, 2020
Common stock - $0.001 par value; 170,000,000 shares authorized, 145,638,459 and 78,074,023 shares issued and outstanding at April 30, 2021 and October 31, 2020, respectively	146	78
Additional paid-in capital	467,227	440,840
Accumulated deficit	(419,822)	(410,738)
Total stockholders' equity	47,551	30,180
Total liabilities and stockholders' equity	$ 55,771	$ 38,526

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Apr. 30, 2021	Oct. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference value	$ 0	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	145,638,459	78,074,023
Common stock, shares outstanding	145,638,459	78,074,023

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Income Statement [Abstract]
Revenue	$ 1,375	$ 250	$ 2,990	$ 253
Operating expenses:
Research and development expenses	4,344	3,922	6,914	8,781
General and administrative expenses	3,352	2,649	6,360	5,679
Total operating expenses	7,696	6,571	13,274	14,460
Loss from operations	(6,321)	(6,321)	(10,284)	(14,207)
Other income (expense):
Interest income, net	2	35	3	101
Net changes in fair value of derivative liabilities	995	14	968	(23)
Other income (expense)	217	(1)	229	(1)
Net loss before income taxes	(5,107)	(6,273)	(9,084)	(14,130)
Income tax expense		50		50
Net loss	$ (5,107)	$ (6,323)	$ (9,084)	$ (14,180)
Net loss per common share, basic and diluted	$ (0.04)	$ (0.10)	$ (0.08)	$ (0.25)
Weighted average number of common shares, basic and diluted	123,145,051	60,572,632	111,895,403	56,107,657

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
OPERATING ACTIVITIES
Net loss	$ (9,084)	$ (14,180)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation	451	452
Employee stock purchase plan expense		1
Loss (gain) on change in value of warrants	(968)	23
Loss on disposal of property and equipment	1,530
Loss on write-down of intangible assets	69
Abandonment of intangible assets		603
Depreciation expense	316	457
Amortization expense of intangible assets	135	181
Amortization of right-of-use asset	327	365
Net gain on write off of right-of-use asset and lease liability	(1,116)
Change in operating assets and liabilities:
Accounts receivable	(1,375)
Prepaid expenses, other current assets and deferred expenses	45	235
Other assets	182	1
Accounts payable and accrued expenses	1,142	(1,161)
Deferred revenue	(165)
Operating lease liabilities	(389)	(397)
Net cash used in operating activities	(8,900)	(13,420)
INVESTING ACTIVITIES
Proceeds from disposal of property and equipment	214
Cost of intangible assets	(268)	(358)
Net cash used in investing activities	(54)	(358)
FINANCING ACTIVITIES
Net proceeds of issuance of common stock and warrants	28,115	9,628
Warrant exercises	3,771
Proceeds from employee stock purchase plan		4
Net cash provided by financing activities	31,886	9,632
Net increase in cash and cash equivalents	22,932	(4,146)
Cash and cash equivalents at beginning of period	25,178	32,363
Cash and cash equivalents at end of period	48,110	28,217
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for taxes		50
SUPPLEMENTAL DISCLOSURE OF NON-CASH AND FINANCING ACTIVITIES
Warrant liability reclassified into equity		$ 2

Nature of Operations

Nature of Operations	6 Months Ended
	Apr. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	1. NATURE OF OPERATIONS Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes Lm Lm Lm Lm TM ● Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants; ● Attacking the tumor by generating a strong, cancer-specific T cell response; and ● Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells. Advaxis’ proprietary Lm Lm Liquidity and Capital Resources Liquidity and Management’s Plans Similar to other development stage biotechnology companies, the Company’s products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its business plans. These losses are expected to continue for the foreseeable future. As of April 30, 2021, the Company had approximately $48.1 million in cash and cash equivalents. Although the Company expects to have sufficient capital to fund its obligations, as they become due, in the ordinary course of business until at least July 2022, the actual amount of cash that it will need to operate is subject to many factors. Over the past year, the Company has taken steps to obtain additional financing, including conducting sales of its common stock through its at-the-market (“ATM”) program through A.G.P./Alliance Global Partners, an equity line financing arrangement with Lincoln Park Capital and the completion of a registered direct offering and concurrent private placement with two healthcare-focused, institutional investors in April 2021, as further described below. The Company received aggregate proceeds of about $3.8 million during the six months ended April 30, 2021 upon the exercise of outstanding warrants, which were payable upon exercise. On April 12, 2021, the Company entered into definitive agreements with two healthcare-focused, institutional investors for the purchase of (i) 17,577,400 shares of common stock, (ii) 7,671,937 pre-funded warrants to purchase 7,671,937 shares of common stock and (iii) registered common share purchase warrants to purchase 11,244,135 shares of common stock ("Accompanying Warrants") in a registered direct offering (the “April 2021 Registered Direct Offering”). The Company also issued to the investors, in a concurrent private placement (the “April 2021 Private Placement” and together with the April 2021 Registered Direct Offering, the “April 2021 Offering”), unregistered common share purchase warrants to purchase 14,005,202 shares of the Company’s common stock (the “Private Placement Warrants”).. The Company received gross proceeds of approximately $20 million, before deducting the fees and expenses payable by us in connection with the April 2021 Offering. On November 27, 2020, the Company completed an underwritten public offering of 26,666,666 shares of common stock and common stock warrants to purchase up to 13,333,333 shares of common stock (the “November 2020 Offering”). On November 24, 2020, the underwriters notified us that they had exercised their option to purchase an additional 3,999,999 shares of common stock and 1,999,999 warrants in full. The Company received gross proceeds of approximately $9.2 million, before deducting the fees and expenses payable by us in connection with the November 2020 Offering. With these funds raised and a reduction in the operating expenses the Company believes that it has enough cash to fund its operations for one year from the date of filing. The Company recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations. The Company does not have any current plans to raise capital in the near term, absent an extraordinary change in circumstances, such as unforeseen liabilities or if we acquire new assets that require additional investment. We do not believe we will need to raise additional capital in the near term because we have a) built a strong balance sheet (including the proceeds from the financing completed in April 2021) and b) executed on our cost reduction plans that have reduced our annual cash burn by greater than 75% over the past few years, securing a cash runway through potential future clinical and corporate milestones.

Summary of Significant Accounti

Summary of Significant Accounting Policies and Basis of Presentation	6 Months Ended
	Apr. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Basis of Presentation	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Basis of Presentation/Estimates The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed balance sheet as of April 30, 2021 has been derived from the Company’s October 31, 2020 audited financial statements. In the opinion of management, the unaudited interim condensed financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented. Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates. These unaudited interim condensed financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2020 and notes thereto contained in the Company’s 2020 Annual Report on Form 10-K, as filed with the SEC on January 22, 2021, and as amended by Amendment No. 1 thereto on Form 10-K/A filed on February 26, 2021. Net Income (Loss) per Share Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share as of April 30, 2021 and April 30, 2020, 0 and 343,838 warrants, respectively, are included in the basic earnings per share computation because the exercise price was $0. As of April 30, 2021 2020 Warrants 30,225,397 5,398,226 Stock options 1,031,323 252,296 Restricted stock units - 5,818 Total 31,256,720 5,946,322 Sequencing Policy The Company adopted a sequencing policy under ASC 815-40-35, if reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares. This was due to the Company committing more shares than authorized. Certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the most recent grant date of potentially dilutive instruments. Pursuant to ASC 815, issuances of securities granted as compensation in a share-based payment arrangement are not subject to the sequencing policy. Leases At the inception of an arrangement, the Company determines whether an arrangement is or contains a lease based on the facts and circumstances present in the arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Most leases with a term greater than one year are recognized on the balance sheet as operating lease right-of-use assets and current and long-term operating lease liabilities, as applicable. In accordance with the Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification (“ASC”) Topic 842, Leases Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued rent. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Recent Accounting Standards Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

Property and Equipment

Property and Equipment	6 Months Ended
	Apr. 30, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment	3. PROPERTY AND EQUIPMENT Property and equipment, net consisted of the following (in thousands): April 30, 2021 October 31, 2020 Leasehold improvements $ - $ 2,335 Laboratory equipment 413 1,218 Furniture and fixtures - 744 Computer equipment 409 409 Construction in progress - 19 Total property and equipment 822 4,725 Accumulated depreciation and amortization (489 ) (2,332 ) Net property and equipment $ 333 $ 2,393 Depreciation expense for the three months ended April 30, 2021 and 2020 was $0.1 million and $0.2 million, respectively. Depreciation expense for the six months ended April 30, 2021 and 2020 was $0.3 million and $0.5 million, respectively. During the three months ended April 30, 2021, the Company incurred a loss on disposal of equipment of $1.5 million, $0.97 million of which is reflected in the research and development expenses and $0.53 million of which is reflected in the general and administrative expenses in the statement of operations.

Intangible Assets

Intangible Assets	6 Months Ended
	Apr. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	4. INTANGIBLE ASSETS Intangible assets, net consisted of the following (in thousands): April 30, 2021 October 31, 2020 Patents $ 4,674 $ 4,479 Licenses 777 777 Software 117 117 Total intangibles 5,568 5,373 Accumulated amortization (2,243 ) (2,112 ) Intangible assets $ 3,325 $ 3,261 The expiration dates of the existing patents range from 2021 to 2040 but the expiration dates can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to further pursue the application. Patent applications having a net book value of $0.1 million and $0.4 million were abandoned and were charged to general and administrative expenses in the statement of operations for each of the three months ended April 30, 2021 and 2020, respectively. Patent applications having a net book value of $0.1 million and $0.6 million were abandoned and were charged to general and administrative expenses in the statement of operations for the six months ended April 30, 2021 and 2020, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the statement of operations aggregated approximately $0.1 million for each of the three months ended April 30, 2021 and 2020, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the statement of operations aggregated $0.1 and $0.2 million for each of the six months ended April 30, 2021 and 2020, respectively. Management has reviewed its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet for patents and licenses related to axalimogene filolisbac (AXAL), ADXS-HOT, ADXS-PSA and ADXS-HER2 and other products that are in development. However, if a competitor were to gain FDA approval for a treatment before us or if future clinical trials fail to meet the targeted endpoints, the Company will likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of its estimated book value. Lastly, if the Company is unable to raise enough capital to continue funding its studies and developing its intellectual property, the Company would likely record an impairment to these assets. As of April 30, 2021, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands): Fiscal year ending October 31, 2021 (Remaining) $ 136 2022 273 2023 273 2024 273 2025 273 Thereafter 2,097 Total $ 3,325

Accrued Expenses

Accrued Expenses	6 Months Ended
	Apr. 30, 2021
Payables and Accruals [Abstract]
Accrued Expenses	5. ACCRUED EXPENSES: The following table summarizes accrued expenses included in the condensed balance sheets (in thousands): April 30, 2021 October 31, 2020 Salaries and other compensation $ 445 $ 737 Vendors 1,357 671 Professional fees 331 329 Total accrued expenses $ 2,133 $ 1,737

Common Stock Purchase Warrants

Common Stock Purchase Warrants and Warrant Liability	6 Months Ended
	Apr. 30, 2021
Common Stock Purchase Warrants And Warrant Liability
Common Stock Purchase Warrants and Warrant Liability	6. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY Warrants As of April 30, 2021, there were outstanding and exercisable warrants to purchase 30,225,397 and 16,220,195 shares, respectively, of our common stock with exercise prices ranging from $0.30 to $281.25 per share. Information on the outstanding warrants is as follows: Exercise Price Number of Shares Underlying Warrants Expiration Date Type of Financing $ 281.25 25 N/A Other warrants $ 0.30 70,297 July 2024 September 2018 Public Offering $ 2.80 327,338 September 2024 July 2019 Public Offering $ 0.35 4,578,400 November 2025 November 2020 Public Offering $ 0.70 11,244,135 April 2026 April 2021 Registered Direct Offering (Accompanying Warrants) $ 0.70 14,005,202 5 years after the date such warrants become exercisable, if ever April 2021 Private Placement (Private Placement Warrants) Grand Total 30,225,397 As of October 31, 2020, there were outstanding warrants to purchase 398,226 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows: Exercise Price Number of Shares Underlying Warrants Expiration Date Type of Financing $ - 327,338 July 2024 July 2019 Public Offering $ 281.25 25 N/A Other Warrants $ 0.372 70,863 September 2024 September 2018 Public Offering Grand Total 398,226 A summary of warrant activity for the six months ended April 30, 2021 is as follows (in thousands, except share and per share data): Warrants Weighted Average Exercise Weighted Average Remaining Contractual In Years Aggregate Intrinsic Outstanding and exercisable warrants at October 31, 2020 398,226 $ 0.08 3.76 $ 110,640 Issued 48,254,606 0.48 5.00 Exercised (18,427,435 ) 0.20 Outstanding and exercisable warrants at April 30, 2021 30,225,397 $ 0.67 4.89 $ 809,752 As of April 30, 2021, the Company had 18,910,965 of its total 30,225,397 outstanding warrants classified as equity (equity warrants). At October 31, 2020, the Company had 327,363 of its total 398,226 outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the relative fair value method, in the stockholders’ equity section of the condensed balance sheets. Warrant Liability As of April 30, 2021, the Company had 11,314,432 of its total 30,225,397 outstanding warrants from April 2021 Private Placement Offering and September 2018 Public Offering classified as liabilities (liability warrants). At October 31, 2020, the Company had 70,863 of its total 398,226 outstanding warrants classified as liabilities (liability warrants). The warrants issued in the April 2021 Private Placement will become exercisable only on such day, if ever, that is fourteen (14) days after the Company files an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock, $0.001 par value per share from 170,000,000 shares to 300,000,000 shares. These warrants expire five years after the date they become exercisable. As a result, liability classification is warranted. For these liability warrants, the Company utilized the Black Scholes model to calculate the fair value of these warrants at issuance and at each subsequent reporting date. In measuring the warrant liability for the warrants issued in the April 2021 Private Placement at April 30, 2021 and April 14, 2021 (issuance date), the Company used the following inputs in its Black Scholes model: April 30, 2021 April 14, 2021 Exercise Price $ 0.70 $ 0.70 Stock Price $ 0.49 $ 0.57 Expected Term 5.00 years 5.00 years Volatility % 106 % 106 % Risk Free Rate 0.86 % 0.85 % The September 2018 Public Offering warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. As of April 30, 2021, the down round feature was triggered three times and the exercise price of the warrants were reduced from $22.50 to $0.30. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which settlement in other than cash would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequent reporting date. In measuring the warrant liability for the September 2018 Public Offering warrants at April 30, 2021 and October 31, 2020, the Company used the following inputs in its Monte Carlo simulation model: April 30, 2021 October 31, 2020 Exercise Price $ 0.30 $ 0.37 Stock Price $ 0.49 $ 0.34 Expected Term 3.37 years 3.87 years Volatility % 120 % 106 % Risk Free Rate 0.35 % 0.29 %

Share Based Compensation

Share Based Compensation	6 Months Ended
	Apr. 30, 2021
Share-based Payment Arrangement [Abstract]
Share Based Compensation	7. SHARE BASED COMPENSATION The following table summarizes share-based compensation expense included in the condensed statements of operations (in thousands): Three Months Ended April 30, Six Months Ended April 30, 2021 2020 2021 2020 Research and development $ 56 $ 62 $ 113 $ 153 General and administrative 159 148 338 299 Total $ 215 $ 210 $ 451 $ 452 Restricted Stock Units (RSUs) A summary of the Company’s RSU activity and related information for the six months ended April 30, 2021 is as follows: Number of Weighted-Average Balance at October 31, 2020 5,556 $ 24.32 Vested (5,555 ) Cancelled (1 ) Balance at April 30, 2021 - $ - As of April 30, 2021, there was no unrecognized compensation cost related to non-vested RSUs. Employee Stock Awards Common Stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 5,888 shares and 5,561 shares during the three months ended April 30, 2021 and 2020, respectively. Total stock compensation expense associated with employee awards for the three months ended April 30, 2021 and 2020 was approximately $30,000 and $40,000, respectively. Common Stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 5,888 shares and 8,608 shares during the six months ended April 30, 2021 and 2020, respectively. Total stock compensation expense associated with employee awards for the six months ended April 30, 2021 and 2020 was approximately $0.1 million and $0.1 million, respectively. Stock Options A summary of changes in the stock option plan for the six months ended April 30, 2021 is as follows: Shares Weighted Weighted Aggregate Outstanding as of October 31, 2020 1,011,768 $ 33.43 8.04 $ 4 Granted 50,000 0.39 Exercised (333 ) 0.30 Cancelled or expired (30,112 ) 10.57 Outstanding as of April 30, 2021 1,031,323 $ 32.51 7.62 $ 28 Vested and exercisable at April 30, 2021 352,747 $ 93.53 4.87 $ 8 Options Outstanding Options Exercisable Weighted Weighted Weighted Weighted Average Average Average Average Exercise Number Remaining Exercise Number Remaining Exercise Price Range Outstanding Contractual Price Exercisable Contractual Price $ .30-$10.00 777.385 8.95 $ 1.04 100,404 8.27 $ 3.02 $ 10.01-$100.00 91,700 6.69 $ 29.17 90,105 6.68 $ 29.35 $ 100.01-$200.00 92,847 2.26 $ 166.04 92,847 2.26 $ 166.04 $ 200.01-$277.50 69,391 1.09 $ 210.79 69,391 1.09 $ 210.79 During the six months ended April 30, 2021, the Company granted options to purchase 50,000 shares of its common stock to an employee. The stock options have a ten-year term, vest over three years from the date of grant, and have an exercise price of $0.39. Total compensation cost related to the Company’s outstanding stock options, recognized in the statement of operations for the three months ended April 30, 2021 and 2020 was approximately $0.2 million and $0.2 million, respectively. For the six months ended April 30, 2021 and 2020, compensation cost related to the Company’s outstanding stock options was approximately $0.4 million and $0.4 million, respectively As of April 30, 2021, there was approximately $0.3 million of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of 1.75 years. As of April 30, 2021, the aggregate intrinsic value of vested and exercisable options was $8 thousand and the aggregate intrinsic value of non-vested options was approximately $28 thousand. In determining the fair value of the stock options granted during the six months ended April 30, 2021, the Company used the following inputs in its Black Scholes Merton model: Six Months Expected Term 6 years Expected Volatility 103.27 % Expected Dividends 0 % Risk Free Interest Rate 0.53 % Employee Stock Purchase Plan During the six months ended April 30, 2021 and 2020, the Company issued 1,000 and 8,249 shares, respectively, that were purchased under the 2018 Employee Stock Purchase Plan (“ESPP”).

Collaboration and Licensing Agr

Collaboration and Licensing Agreements	6 Months Ended
	Apr. 30, 2021
Business Combinations [Abstract]
Collaboration and Licensing Agreements	8. COLLABORATION AND LICENSING AGREEMENTS OS Therapies LLC On September 4, 2018, the Company entered into a development, license and supply agreement with OS Therapies (“OST”) for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, as amended, OST will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. Under the most recent amendment to the licensing agreement, OST agreed to pay Advaxis $25,000 per month (“Monthly Payment”) starting on April 30, 2020 until it achieved its funding milestone of $2,337,500. Upon receipt of the first Monthly Payment, Advaxis initiated the transfer of the intellectual property and licensing rights of ADXS31-164, which were licensed pursuant to the Penn Agreement, back to the University of Pennsylvania. Contemporaneously, OST will enter negotiations with the University of Pennsylvania to establish a licensing agreement for ADXS31-164 to OST for clinical and commercial development of the ADXS31-164 technology. In December 2020 and January 2021, the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement. The Company therefore transferred and OST took full ownership of, the IND application for ADXS31-164 in its entirety along with agreements and promises contained therein, as well as all obligations associated with this IND or any HER2 product/program development. On April 26, 2021, the Company achieved the second milestone set forth in the license agreement for evaluation in the treatment of osteosarcoma in humans. The Company has a receivable due from OS Therapies of $1.375 million at April 30, 2021.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Apr. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. COMMITMENTS AND CONTINGENCIES Legal Proceedings The Company is from time to time involved in legal proceedings in the ordinary course of our business. The Company does not believe that any of these claims or proceedings against us is likely to have, individually or in the aggregate, a material adverse effect on the financial condition or results of operations.

Leases

Leases	6 Months Ended
	Apr. 30, 2021
Leases [Abstract]
Leases	10. LEASES Operating Leases The Company previously leased a corporate office and manufacturing facility in Princeton, New Jersey under an operating lease that was set to expire in November 2025. On March 26, 2021, the Company entered into a Lease Termination and Surrender Agreement with respect to this lease agreement. The Lease Termination and Surrender Agreement provides for the early termination of the lease, which became effective on March 31, 2021. In connection with the early termination of the lease, the Company was required to pay a $1,000,000 termination payment. The unapplied security deposit totaling approximately $182,000 was credited against the termination fee for a net payment of approximately $817,000. During the three months ended April 30, 2021, the Company wrote off of the remaining right-of-use asset of $4.5 million and lease liability of $5.6 million. After consideration of the termination payment and write off of remaining right-of-use asset and lease liability, the Company recorded a net gain of $0.1 million. On March 25, 2021, the Company entered into a new lease agreement for its corporate office/lab with base rent of approximately $29,000 per year, plus other expenses. The lease expires on March 25, 2022 and the Company has the option to renew the lease for one additional successive one year term upon six months written notice to the landlord. This new lease is accounted for as a short-term lease and the Company has elected to not recognize the right-of-use asset and lease liability. As a result of the termination of the Company's prior lease agreement pursuant to the Lease Termination and Surrender Agreement, the Company does not have an outstanding lease liability or operating right-of-use asset recorded as of April 30, 2021. Supplemental lease expense related to leases was as follows (in thousands): Lease Cost (in thousands) Statements of Operations Classification For the Three For the Six Operating lease cost General and administrative 1,011 1,301 Short-term lease cost General and administrative 16 16 Variable lease cost General and administrative $ 61 159 Total lease expense $ 1,088 1,476 Lease Cost (in thousands) Statements of Operations Classification For the Three For the Six Operating lease cost General and administrative 289 579 Short-term lease cost General and administrative 85 169 Variable lease cost General and administrative $ 129 270 Total lease expense $ 503 1,018 Supplemental cash flow information related to operating leases was as follows: For the Three For the Six Cash paid for operating lease liabilities $ 1,039 1,363 For the Three For the Six Cash paid for operating lease liabilities $ 311 611

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Apr. 30, 2021
Equity [Abstract]
Stockholders' Equity	11. STOCKHOLDERS’ EQUITY Public Offerings On April 12, 2021, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors. The Purchase Agreement provided for the sale and issuance by the Company of an aggregate of 17,577,400 shares (the “Shares”) of the Company’s common stock, $0.001 par value (the “Common Stock”), at an offering price of $0.7921 per Share and 7,671,937 pre-funded warrants to certain purchasers whose purchase of additional Shares would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 9.99% of the Company’s outstanding Common Stock immediately following the consummation of the offering (the “Pre-Funded Warrants”). The Shares and Pre-Funded Warrants were sold together with warrants to purchase up to 11,244,135 shares of Common Stock (the “Accompanying Warrants” and together with the Shares and the Pre-Funded Warrants, the “Securities”). The Pre-Funded Warrants were sold for a purchase price of $0.7911 per share and have an exercise price of $0.001 per share. The Pre-Funded Warrants were immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. Each Accompanying Warrant has an exercise price per share of $0.70, became exercisable immediately and will expire on the fifth anniversary of the original issuance date. The Purchase Agreement also provided for a concurrent private placement (the “Private Placement”) of 14,005,202 warrants to purchase the Company’s Common Stock (the “Private Placement Warrants”) with the purchasers in the Registered Offering. The Private Placement Warrants will be exercisable for an aggregate of 14,005,202 shares of Common Stock at any time on or after such date, if ever, that is fourteen (14) days after the Company files an amendment (the “Authorized Shares Amendment”) to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock, $0.001 par value per share from 170,000,000 shares to 300,000,000 shares with the Delaware Secretary of State and on or prior to the date that is five years after such date. The Private Placement Warrants have an exercise price of $0.70 per share. In March 2021, the Company sold 886,048 shares of its common stock via the at-the-market (“ATM”) program through A.G.P./Alliance Global Partners netting about $0.7 million in proceeds. In November 2020, the Company closed on a public offering of 30,666,665 shares of its common stock at a public offering price of $0.30 per share, for gross proceeds of $9.2 million, which gives effect to the exercise of the underwriter’s option in full. In addition, the Company also undertook a concurrent private placement of warrants to purchase up to 15,333,332 shares of common stock. The warrants have an exercise price per share of $0.35, are exercisable immediately and will expire five years from the date of issuance. The warrants also provide that if there is no effective registration statement registering, or no current prospectus available for, the issuance or resale of the warrant shares, the warrants may be exercised via a cashless exercise. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $8.5 million. During the six months ended April 30, 2021, warrant holders from the Company’s November 2020 offering exercised 10,754,932 warrants in exchange for 10,754,932 shares of the Company’s common stock and warrant holders from the Company’s April 2021 Offering exercised 7,671,937 pre-funded warrants in exchange for 7,671,937 shares of the Company’s common stock. Pursuant to these warrant exercises, the Company received aggregate proceeds of approximately $3.8 million which were payable upon exercise. A summary of the changes in stockholders’ equity for the three and six months ended April 30, 2021 and 2020 is presented below (in thousands, except share data): Preferred Stock Common Stock Additional Accumulated Total Shares Amount Shares Amount Capital Deficit Equity Balance at November 1, 2019 - $ - 50,201,671 $ 50 $ 423,750 $ (384,269 ) $ 39,531 Stock-based compensation - - 2,957 - 242 - 242 Advaxis public offerings, net of offering costs - - 10,000,000 10 9,618 - 9,628 Warrant exercises - - 26,416 - 2 - 2 Issuance of shares to employees under ESPP Plan - - 5,555 - 2 - 2 Net Loss - - - - - (7,857 ) (7,857 ) Balance at January 31, 2020 - $ - 60,236,599 $ 60 $ 433,614 $ (392,126 ) $ 41,548 Stock-based compensation - - 5,651 - 210 - 210 Warrant exercises - - 7,500 - - - - Issuance of shares to employees under ESPP Plan - - 2,694 - 2 - 2 Net Loss - - - - - (6,323 ) (6,323 ) Balance at April 30, 2020 - $ - 60,252,444 $ 60 $ 433,826 $ (398,449 ) $ 35,437 Preferred Stock Common Stock Additional Paid-In Accumulated Total Shareholders’ Shares Amount Shares Amount Capital Deficit Equity Balance at November 1, 2020 - $ - 78,074,023 $ 78 $ 440,840 $ (410,738 ) $ 30,180 Stock-based compensation - - - - 236 - 236 Advaxis public offerings, net of offering costs - - 30,666,665 31 8,519 - 8,550 Warrant exercises - - 7,390,000 7 2,579 - 2,586 Net Loss - - - - - (3,977 ) (3,977 ) Balance at January 31, 2021 - $ - 116,130,688 $ 116 $ 452,174 $ (414,715 ) $ 37,575 Stock-based compensation - - 5,888 - 215 - 215 Advaxis public offerings, net of offering costs - - 18,463,448 19 13,664 - 13,683 Warrant exercises - - 11,037,435 11 1,174 - 1,185 Issuance of shares to employees under ESPP Plan - - 1,000 - - - - Net Loss - - - - - (5,107 ) (5,107 ) Balance at April 30, 2021 - $ - 145,638,459 $ 146 $ 467,227 $ (419,822 ) $ 47,551

Fair Value

Fair Value	6 Months Ended
	Apr. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value	12. FAIR VALUE The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: ● Level 1 — Quoted prices in active markets for identical assets or liabilities. ● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities. ● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities. The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of April 30, 2021 and October 31, 2020 (in thousands): April 30, 2021 Level 1 Level 2 Level 3 Total Common stock warrant liability, warrants exercisable at $0.30 through September 2024 - - $ 29 $ 29 Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants) - - $ 4,902 $ 4,902 Total - - $ 4,931 $ 4,931 October 31, 2020 Level 1 Level 2 Level 3 Total Common stock warrant liability, warrants exercisable at $0.372 through September 2024 - - $ 17 $ 17 The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities (in thousands): For the Beginning balance $ 17 Warrants issued 5,882 Warrant exercises - Change in fair value (968 ) Ending Balance $ 4,931

Subsequent Events

Subsequent Events	6 Months Ended
	Apr. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events None.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Basis of Presentation (Policies)	6 Months Ended
	Apr. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation/Estimates	Basis of Presentation/Estimates The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed balance sheet as of April 30, 2021 has been derived from the Company’s October 31, 2020 audited financial statements. In the opinion of management, the unaudited interim condensed financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented. Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates. These unaudited interim condensed financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2020 and notes thereto contained in the Company’s 2020 Annual Report on Form 10-K, as filed with the SEC on January 22, 2021, and as amended by Amendment No. 1 thereto on Form 10-K/A filed on February 26, 2021.
Net Income (Loss) Per Share	Net Income (Loss) per Share Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share as of April 30, 2021 and April 30, 2020, 0 and 343,838 warrants, respectively, are included in the basic earnings per share computation because the exercise price was $0. As of April 30, 2021 2020 Warrants 30,225,397 5,398,226 Stock options 1,031,323 252,296 Restricted stock units - 5,818 Total 31,256,720 5,946,322
Sequencing Policy	Sequencing Policy The Company adopted a sequencing policy under ASC 815-40-35, if reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares. This was due to the Company committing more shares than authorized. Certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the most recent grant date of potentially dilutive instruments. Pursuant to ASC 815, issuances of securities granted as compensation in a share-based payment arrangement are not subject to the sequencing policy.
Leases	Leases At the inception of an arrangement, the Company determines whether an arrangement is or contains a lease based on the facts and circumstances present in the arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Most leases with a term greater than one year are recognized on the balance sheet as operating lease right-of-use assets and current and long-term operating lease liabilities, as applicable. In accordance with the Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification (“ASC”) Topic 842, Leases Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued rent. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.
Recent Accounting Standards	Recent Accounting Standards Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Basis of Presentation (Tables)	6 Months Ended
	Apr. 30, 2021
Accounting Policies [Abstract]
Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share	The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share as of April 30, 2021 and April 30, 2020, 0 and 343,838 warrants, respectively, are included in the basic earnings per share computation because the exercise price was $0. As of April 30, 2021 2020 Warrants 30,225,397 5,398,226 Stock options 1,031,323 252,296 Restricted stock units - 5,818 Total 31,256,720 5,946,322

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Apr. 30, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consisted of the following (in thousands): April 30, 2021 October 31, 2020 Leasehold improvements $ - $ 2,335 Laboratory equipment 413 1,218 Furniture and fixtures - 744 Computer equipment 409 409 Construction in progress - 19 Total property and equipment 822 4,725 Accumulated depreciation and amortization (489 ) (2,332 ) Net property and equipment $ 333 $ 2,393

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Apr. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets	Intangible assets, net consisted of the following (in thousands): April 30, 2021 October 31, 2020 Patents $ 4,674 $ 4,479 Licenses 777 777 Software 117 117 Total intangibles 5,568 5,373 Accumulated amortization (2,243 ) (2,112 ) Intangible assets $ 3,325 $ 3,261
Schedule of Carrying Value of Intangible Assets	As of April 30, 2021, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands): Fiscal year ending October 31, 2021 (Remaining) $ 136 2022 273 2023 273 2024 273 2025 273 Thereafter 2,097 Total $ 3,325

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Apr. 30, 2021
Payables and Accruals [Abstract]
Summary of Accrued Expenses	The following table summarizes accrued expenses included in the condensed balance sheets (in thousands): April 30, 2021 October 31, 2020 Salaries and other compensation $ 445 $ 737 Vendors 1,357 671 Professional fees 331 329 Total accrued expenses $ 2,133 $ 1,737

Common Stock Purchase Warrant_2

Common Stock Purchase Warrants and Warrant Liability (Tables)	6 Months Ended
	Apr. 30, 2021
Schedule of Outstanding Warrants	As of April 30, 2021, there were outstanding and exercisable warrants to purchase 30,225,397 and 16,220,195 shares, respectively, of our common stock with exercise prices ranging from $0.30 to $281.25 per share. Information on the outstanding warrants is as follows: Exercise Price Number of Shares Underlying Warrants Expiration Date Type of Financing $ 281.25 25 N/A Other warrants $ 0.30 70,297 July 2024 September 2018 Public Offering $ 2.80 327,338 September 2024 July 2019 Public Offering $ 0.35 4,578,400 November 2025 November 2020 Public Offering $ 0.70 11,244,135 April 2026 April 2021 Registered Direct Offering (Accompanying Warrants) $ 0.70 14,005,202 5 years after the date such warrants become exercisable, if ever April 2021 Private Placement (Private Placement Warrants) Grand Total 30,225,397 As of October 31, 2020, there were outstanding warrants to purchase 398,226 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows: Exercise Price Number of Shares Underlying Warrants Expiration Date Type of Financing $ - 327,338 July 2024 July 2019 Public Offering $ 281.25 25 N/A Other Warrants $ 0.372 70,863 September 2024 September 2018 Public Offering Grand Total 398,226
Schedule of Warrants Activity	A summary of warrant activity for the six months ended April 30, 2021 is as follows (in thousands, except share and per share data): Warrants Weighted Average Exercise Weighted Average Remaining Contractual In Years Aggregate Intrinsic Outstanding and exercisable warrants at October 31, 2020 398,226 $ 0.08 3.76 $ 110,640 Issued 48,254,606 0.48 5.00 Exercised (18,427,435 ) 0.20 Outstanding and exercisable warrants at April 30, 2021 30,225,397 $ 0.67 4.89 $ 809,752
Schedule of Assumptions Used in Warrant Liability	In measuring the warrant liability for the warrants issued in the April 2021 Private Placement at April 30, 2021 and April 14, 2021 (issuance date), the Company used the following inputs in its Black Scholes model: April 30, 2021 April 14, 2021 Exercise Price $ 0.70 $ 0.70 Stock Price $ 0.49 $ 0.57 Expected Term 5.00 years 5.00 years Volatility % 106 % 106 % Risk Free Rate 0.86 % 0.85 %
Private Placement [Member]
Schedule of Assumptions Used in Warrant Liability	In measuring the warrant liability for the September 2018 Public Offering warrants at April 30, 2021 and October 31, 2020, the Company used the following inputs in its Monte Carlo simulation model: April 30, 2021 October 31, 2020 Exercise Price $ 0.30 $ 0.37 Stock Price $ 0.49 $ 0.34 Expected Term 3.37 years 3.87 years Volatility % 120 % 106 % Risk Free Rate 0.35 % 0.29 %

Share Based Compensation (Table

Share Based Compensation (Tables)	6 Months Ended
	Apr. 30, 2021
Share-based Payment Arrangement [Abstract]
Summary of Share Based Compensation Expense	The following table summarizes share-based compensation expense included in the condensed statements of operations (in thousands): Three Months Ended April 30, Six Months Ended April 30, 2021 2020 2021 2020 Research and development $ 56 $ 62 $ 113 $ 153 General and administrative 159 148 338 299 Total $ 215 $ 210 $ 451 $ 452
Summary of RSU Activity and Related Information	Restricted Stock Units (RSUs) A summary of the Company’s RSU activity and related information for the six months ended April 30, 2021 is as follows: Number of Weighted-Average Balance at October 31, 2020 5,556 $ 24.32 Vested (5,555 ) Cancelled (1 ) Balance at April 30, 2021 - $ -
Summary of Changes in Stock Option Plan	A summary of changes in the stock option plan for the six months ended April 30, 2021 is as follows: Shares Weighted Weighted Aggregate Outstanding as of October 31, 2020 1,011,768 $ 33.43 8.04 $ 4 Granted 50,000 0.39 Exercised (333 ) 0.30 Cancelled or expired (30,112 ) 10.57 Outstanding as of April 30, 2021 1,031,323 $ 32.51 7.62 $ 28 Vested and exercisable at April 30, 2021 352,747 $ 93.53 4.87 $ 8
Summary of Outstanding and Exercisable Options	Options Outstanding Options Exercisable Weighted Weighted Weighted Weighted Average Average Average Average Exercise Number Remaining Exercise Number Remaining Exercise Price Range Outstanding Contractual Price Exercisable Contractual Price $ .30-$10.00 777.385 8.95 $ 1.04 100,404 8.27 $ 3.02 $ 10.01-$100.00 91,700 6.69 $ 29.17 90,105 6.68 $ 29.35 $ 100.01-$200.00 92,847 2.26 $ 166.04 92,847 2.26 $ 166.04 $ 200.01-$277.50 69,391 1.09 $ 210.79 69,391 1.09 $ 210.79
Summary of Fair Value of Stock Options Granted of BSM	In determining the fair value of the stock options granted during the six months ended April 30, 2021, the Company used the following inputs in its Black Scholes Merton model: Six Months Expected Term 6 years Expected Volatility 103.27 % Expected Dividends 0 % Risk Free Interest Rate 0.53 %

Leases (Tables)

Leases (Tables)	6 Months Ended
	Apr. 30, 2021
Leases [Abstract]
Schedule of Lease Expenses	Supplemental lease expense related to leases was as follows (in thousands): Lease Cost (in thousands) Statements of Operations Classification For the Three For the Six Operating lease cost General and administrative 1,011 1,301 Short-term lease cost General and administrative 16 16 Variable lease cost General and administrative $ 61 159 Total lease expense $ 1,088 1,476 Lease Cost (in thousands) Statements of Operations Classification For the Three For the Six Operating lease cost General and administrative 289 579 Short-term lease cost General and administrative 85 169 Variable lease cost General and administrative $ 129 270 Total lease expense $ 503 1,018
Schedule of Cash Flow Information Related to Leases	Supplemental cash flow information related to operating leases was as follows: For the Three For the Six Cash paid for operating lease liabilities $ 1,039 1,363 For the Three For the Six Cash paid for operating lease liabilities $ 311 611

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Apr. 30, 2021
Equity [Abstract]
Summary of Stockholders Equity	A summary of the changes in stockholders’ equity for the three and six months ended April 30, 2021 and 2020 is presented below (in thousands, except share data): Preferred Stock Common Stock Additional Accumulated Total Shares Amount Shares Amount Capital Deficit Equity Balance at November 1, 2019 - $ - 50,201,671 $ 50 $ 423,750 $ (384,269 ) $ 39,531 Stock-based compensation - - 2,957 - 242 - 242 Advaxis public offerings, net of offering costs - - 10,000,000 10 9,618 - 9,628 Warrant exercises - - 26,416 - 2 - 2 Issuance of shares to employees under ESPP Plan - - 5,555 - 2 - 2 Net Loss - - - - - (7,857 ) (7,857 ) Balance at January 31, 2020 - $ - 60,236,599 $ 60 $ 433,614 $ (392,126 ) $ 41,548 Stock-based compensation - - 5,651 - 210 - 210 Warrant exercises - - 7,500 - - - - Issuance of shares to employees under ESPP Plan - - 2,694 - 2 - 2 Net Loss - - - - - (6,323 ) (6,323 ) Balance at April 30, 2020 - $ - 60,252,444 $ 60 $ 433,826 $ (398,449 ) $ 35,437 Preferred Stock Common Stock Additional Paid-In Accumulated Total Shareholders’ Shares Amount Shares Amount Capital Deficit Equity Balance at November 1, 2020 - $ - 78,074,023 $ 78 $ 440,840 $ (410,738 ) $ 30,180 Stock-based compensation - - - - 236 - 236 Advaxis public offerings, net of offering costs - - 30,666,665 31 8,519 - 8,550 Warrant exercises - - 7,390,000 7 2,579 - 2,586 Net Loss - - - - - (3,977 ) (3,977 ) Balance at January 31, 2021 - $ - 116,130,688 $ 116 $ 452,174 $ (414,715 ) $ 37,575 Stock-based compensation - - 5,888 - 215 - 215 Advaxis public offerings, net of offering costs - - 18,463,448 19 13,664 - 13,683 Warrant exercises - - 11,037,435 11 1,174 - 1,185 Issuance of shares to employees under ESPP Plan - - 1,000 - - - - Net Loss - - - - - (5,107 ) (5,107 ) Balance at April 30, 2021 - $ - 145,638,459 $ 146 $ 467,227 $ (419,822 ) $ 47,551

Fair Value (Tables)

Fair Value (Tables)	6 Months Ended
	Apr. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of April 30, 2021 and October 31, 2020 (in thousands): April 30, 2021 Level 1 Level 2 Level 3 Total Common stock warrant liability, warrants exercisable at $0.30 through September 2024 - - $ 29 $ 29 Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants) - - $ 4,902 $ 4,902 Total - - $ 4,931 $ 4,931 October 31, 2020 Level 1 Level 2 Level 3 Total Common stock warrant liability, warrants exercisable at $0.372 through September 2024 - - $ 17 $ 17
Schedule of Changes in Fair Value of Warrant Liabilities	The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities (in thousands): For the Beginning balance $ 17 Warrants issued 5,882 Warrant exercises - Change in fair value (968 ) Ending Balance $ 4,931

Nature of Operations (Details N

Nature of Operations (Details Narrative) - USD ($) $ in Thousands	Apr. 12, 2021	Nov. 27, 2020	Nov. 24, 2020	Nov. 30, 2020	Apr. 30, 2021	Jan. 31, 2021	Apr. 30, 2020	Jan. 31, 2020	Apr. 30, 2021	Apr. 30, 2020	Oct. 31, 2020
Cash and cash equivalents					$ 48,110				$ 48,110		$ 25,178
Proceeds from warrant exercise									$ 3,771
Number of shares issued
Number of warrants to purchase common stock					30,225,397				30,225,397		398,226
Options exercised									333
Warrant exercises					$ 1,185	$ 2,586		$ 2
Capital description									The Company does not have any current plans to raise capital in the near term, absent an extraordinary change in circumstances, such as unforeseen liabilities or if we acquire new assets that require additional investment. We do not believe we will need to raise additional capital in the near term because we have a) built a strong balance sheet (including the proceeds from the financing completed in April 2021) and b) executed on our cost reduction plans that have reduced our annual cash burn by greater than 75% over the past few years, securing a cash runway through potential future clinical and corporate milestones.
Public Offering [Member]
Number of shares issued		26,666,666
Pre-funded warrants to purchase common shares					7,671,937				7,671,937
Number of warrants to purchase common stock					10,754,932				10,754,932
Proceeds from sale of common shares				$ 9,200
November 2020 Offering [Member]
Number of warrants to purchase common stock		13,333,333
Proceeds from sale of common shares			$ 9,200
Underwriters [Member]
Options exercised			3,999,999
Warrant exercises			$ 1,999,999
Definitive Agreements [Member]
Number of warrants to purchase common stock	11,244,135
Definitive Agreements [Member] | April 2021 Offering [Member]
Number of warrants to purchase common stock	14,005,202
Proceeds from sale of common shares	$ 20,000
Definitive Agreements [Member] | Investor [Member]
Number of shares issued	17,577,400
Pre-funded warrants to purchase common shares	7,671,937
Number of warrants to purchase common stock	7,671,937

Summary of Significant Accoun_4

Summary of Significant Accounting Policies and Basis of Presentation (Details Narrative) - $ / shares	6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
Number of securities included in computation of basic earnings per share	31,256,720	5,946,322
Exercise price	$ 0	$ 0
Warrants [Member]
Number of securities included in computation of basic earnings per share	0	343,838

Summary of Significant Accoun_5

Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share (Details) - shares	6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
Total	31,256,720	5,946,322
Warrants [Member]
Total	30,225,397	5,398,226
Stock Options [Member]
Total	1,031,323	252,296
Restricted Stock Units [Member]
Total		5,818

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Depreciation expense	$ 100	$ 200	$ 316	$ 457
Loss on disposal of equipment	1,500		$ 1,530
Research and Development [Member]
Loss on disposal of equipment	970
General and Administrative [Member]
Loss on disposal of equipment	$ 530

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Apr. 30, 2021	Oct. 31, 2020
Property, Plant and Equipment [Abstract]
Leasehold improvements		$ 2,335
Laboratory equipment	413	1,218
Furniture and fixtures		744
Computer equipment	409	409
Construction in progress		19
Total property and equipment	822	4,725
Accumulated depreciation and amortization	(489)	(2,332)
Net property and equipment	$ 333	$ 2,393

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Expiration of patents description			The expiration dates of the existing patents range from 2021 to 2040.
Book value patent applications, net				$ 603
Intangible asset amortization expense			135	181
General and Administrative [Member]
Book value patent applications, net	$ 400	$ 100	100	600
Intangible asset amortization expense	$ 100	$ 100	$ 100	$ 200

Intangible Assets - Summary of

Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	Apr. 30, 2021	Oct. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 4,674	$ 4,479
Licenses	777	777
Software	117	117
Total intangibles	5,568	5,373
Accumulated amortization	(2,243)	(2,112)
Intangible assets	$ 3,325	$ 3,261

Intangible Assets - Schedule of

Intangible Assets - Schedule of Carrying Value of Intangible Assets (Details) $ in Thousands	Apr. 30, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2021 (Remaining)	$ 136
2022	273
2023	273
2024	273
2025	273
Thereafter	2,097
Total	$ 3,325

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Apr. 30, 2021	Oct. 31, 2020
Payables and Accruals [Abstract]
Salaries and other compensation	$ 445	$ 737
Vendors	1,357	671
Professional fees	331	329
Total accrued expenses	$ 2,133	$ 1,737

Common Stock Purchase Warrant_3

Common Stock Purchase Warrants and Warrant Liability (Details Narrative) - $ / shares	Apr. 30, 2021	Oct. 31, 2020
Class of Warrant or Right [Line Items]
Warrants outstanding	30,225,397
Number of warrants to purchase common stock	30,225,397	398,226
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	170,000,000	170,000,000
Public Offering [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock	10,754,932
Common stock, shares authorized	300,000,000
Equity Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock	18,910,965	327,363
Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock	11,314,432	70,863
Warrant exercise price per share	$ 0.30	$ 0.37
Minimum [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share	0.30	0
Minimum [Member] | Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share	0.30
Maximum [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share	281.25	$ 281.25
Maximum [Member] | Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share	$ 22.50

Common Stock Purchase Warrant_4

Common Stock Purchase Warrants and Warrant Liability - Schedule of Outstanding Warrants (Details) - $ / shares	6 Months Ended	12 Months Ended
	Apr. 30, 2021	Oct. 31, 2020
Class of Warrant or Right [Line Items]
Number of Shares Underlying Warrants	30,225,397	398,226
Exercise Price Range One [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 281.25
Number of Shares Underlying Warrants	25	327,338
Expiration Date		Jul. 31, 2024
Type of Financing	Other warrants	July 2019 Public Offering
Exercise Price Range Two [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.30	$ 281.25
Number of Shares Underlying Warrants	70,297	25
Expiration Date	Jul. 31, 2024
Type of Financing	September 2018 Public Offering	Other Warrants
Exercise Price Range Three [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 2.80	$ 0.372
Number of Shares Underlying Warrants	327,338	70,863
Expiration Date	Sep. 30, 2024	Sep. 30, 2024
Type of Financing	July 2019 Public Offering	September 2018 Public Offering
Exercise Price Range Four [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.35
Number of Shares Underlying Warrants	4,578,400
Expiration Date	Nov. 30, 2025
Type of Financing	November 2020 Public Offering
Exercise Price Range Five [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.70
Number of Shares Underlying Warrants	11,244,135
Expiration Date	Apr. 30, 2026
Type of Financing	April 2021 Registered Direct Offering (Accompanying Warrants)
Exercise Price Range Six [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.70
Number of Shares Underlying Warrants	14,005,202
Type of Financing	April 2021 Private Placement (Private Placement Warrants)
Expiration date description	5 years after the date such warrants become exercisable, if ever

Common Stock Purchase Warrant_5

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Apr. 30, 2021USD ($)$ / sharesshares
Common Stock Purchase Warrants And Warrant Liability
Warrants, Outstanding and exercisable warrants, Beginning balance | shares	398,226
Warrants, Issued | shares	48,254,606
Warrants, Exercised | shares	(18,427,435)
Warrants, Outstanding and exercisable warrants, Ending balance | shares	30,225,397
Weighted Average Exercise Price, Outstanding and exercisable warrants, Beginning | $ / shares	$ 0.08
Weighted Average Exercise Price, Issued | $ / shares	0.48
Weighted Average Exercise Price, Exercised | $ / shares	0.20
Weighted Average Exercise Price, Outstanding and exercisable warrants, Ending | $ / shares	$ 0.67
Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Beginning	3 years 9 months 3 days
Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Issued	5 years
Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Ending balance	4 years 10 months 21 days
Aggregate Intrinsic Value, Beginning | $	$ 110,640
Aggregate Intrinsic Value, Ending | $	$ 809,752

Common Stock Purchase Warrant_6

Common Stock Purchase Warrants and Warrant Liability - Schedule of Assumptions Used in Warrant Liability (Details)	Apr. 30, 2021$ / shares	Apr. 14, 2021$ / shares	Nov. 30, 2020$ / shares	Oct. 31, 2020$ / shares	Apr. 30, 2020$ / shares
Class of Warrant or Right [Line Items]
Stock Price	$ 0				$ 0
Private Placement [Member]
Class of Warrant or Right [Line Items]
Exercise Price			$ 0.35
Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Exercise Price	0.30			$ 0.37
Stock Price	$ 0.49			$ 0.34
Warrant Liability [Member] | Expected Term [Member]
Class of Warrant or Right [Line Items]
Expected Term	3 years 4 months 13 days			3 years 10 months 14 days
Warrant Liability [Member] | Volatility [Member]
Class of Warrant or Right [Line Items]
Measurement input percentage	120			106
Warrant Liability [Member] | Risk Free Rate [Member]
Class of Warrant or Right [Line Items]
Measurement input percentage	0.35			0.29
Warrant Liability [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.70	$ 0.70
Stock Price	$ 0.49	$ 0.57
Warrant Liability [Member] | Private Placement [Member] | Expected Term [Member]
Class of Warrant or Right [Line Items]
Expected Term	5 years	5 years
Warrant Liability [Member] | Private Placement [Member] | Volatility [Member]
Class of Warrant or Right [Line Items]
Measurement input percentage	106	106
Warrant Liability [Member] | Private Placement [Member] | Risk Free Rate [Member]
Class of Warrant or Right [Line Items]
Measurement input percentage	0.86	0.85

Share Based Compensation (Detai

Share Based Compensation (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Apr. 30, 2021	Jan. 31, 2021	Apr. 30, 2020	Jan. 31, 2020	Apr. 30, 2021	Apr. 30, 2020	Oct. 31, 2020
Unrecognized compensation cost related to non-vested stock option awards	$ 300,000				$ 300,000
Share-based compensation, common stock, shares
Stock compensation expense	$ 215,000		$ 210,000		$ 451,000	$ 452,000
Stock granted options to purchase					50,000
Stock option term					P10Y
Stock option vesting period					3 years
Stock option exercise price	$ 32.51				$ 32.51		$ 33.43
Compensation cost related to outstanding stock options	$ 200,000		$ 200,000		$ 400,000	$ 400,000
Unrecognized compensation cost related to non-vested remaining weighted average vesting period					1 year 9 months
Aggregate intrinsic value of vested and exercisable options	8,000				$ 8,000
Aggregate intrinsic value of non-vested options	$ 28,000				28,000		$ 4,000
Number of shares issued under employee stock purchase plan
Restricted Stock Units (RSUs) [Member]
Unrecognized compensation cost related to non-vested stock option awards
Employee Stock Awards [Member]
Share-based compensation, common stock, shares	5,888		5,561		5,888	8,608
Stock compensation expense	$ 30,000		$ 40,000		$ 100,000	$ 100,000
2018 Employee Stock Purchase Plan [Member]
Number of shares issued under employee stock purchase plan					1,000	8,249

Share Based Compensation - Summ

Share Based Compensation - Summary of Share Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Share-based compensation expense	$ 215	$ 210	$ 451	$ 452
Research and Development [Member]
Share-based compensation expense	56	62	113	153
General and Administrative [Member]
Share-based compensation expense	$ 159	$ 148	$ 338	$ 299

Share Based Compensation - Su_2

Share Based Compensation - Summary of RSU Activity and Related Information (Details) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Apr. 30, 2021$ / sharesshares
Number of RSUs, Unvested Beginning Balance | shares	5,556
Number of RSUs, Vested | shares	(5,555)
Number of RSUs, Cancelled | shares	(1)
Number of RSUs, Unvested Ending Balance | shares
Weighted-Average Grant Date Fair Value, Unvested Beginning Balance | $ / shares	$ 24.32
Weighted-Average Grant Date Fair Value, Vested | $ / shares
Weighted-Average Grant Date Fair Value, Cancelled | $ / shares
Weighted-Average Grant Date Fair Value, Unvested Ending Balance | $ / shares

Share Based Compensation - Su_3

Share Based Compensation - Summary of Changes in Stock Option Plan (Details)	6 Months Ended
	Apr. 30, 2021USD ($)$ / sharesshares
Share-based Payment Arrangement [Abstract]
Shares, Outstanding, Beginning Balance | shares	1,011,768
Shares, Granted | shares	50,000
Shares, Exercised | shares	(333)
Shares, Cancelled or Expired | shares	(30,112)
Shares, Outstanding, Ending Balance | shares	1,031,323
Shares, Vested and Exercisable | shares	352,747
Weighted Average Exercise Price, Outstanding, Beginning | $ / shares	$ 33.43
Weighted Average Exercise Price, Granted | $ / shares	0.39
Weighted average exercise price, Exercised | $ / shares	0.30
Weighted Average Exercise Price, Cancelled or Expired | $ / shares	10.57
Weighted Average Exercise Price, Outstanding, Ending | $ / shares	32.51
Weighted Average Exercise Price, Vested and Exercisable | $ / shares	$ 93.53
Weighted Average Remaining Contractual Life In Years, Outstanding, Beginning	8 years 15 days
Weighted Average Remaining Contractual Life In Years, Outstanding, Ending balance	7 years 7 months 13 days
Weighted Average Remaining Contractual Life In Years, Vested and Exercisable	4 years 10 months 14 days
Aggregate Intrinsic Value, Beginning | $	$ 4,000
Aggregate Intrinsic Value, Ending | $	28,000
Aggregate Intrinsic Value, Vested and Exercisable | $	$ 8,000

Share Based Compensation - Su_4

Share Based Compensation - Summary of Outstanding and Exercisable Options (Details)	6 Months Ended
	Apr. 30, 2021$ / sharesshares
Exercise Price Range One [Member]
Exercise Price Range, lower limit	$ 0.30
Exercise Price Range, upper limit	$ 10
Number Outstanding, Options Outstanding | shares	777.385
Weighted Average Remaining Contractual, Options Outstanding	8 years 11 months 12 days
Weighted Average Exercise Price, Options Outstanding	$ 1.04
Number Outstanding, Options Exercisable | shares	100,404
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	8 years 3 months 8 days
Weighted Average Exercise Price, Options Exercisable	$ 3.02
Exercise Price Range Two [Member]
Exercise Price Range, lower limit	10.01
Exercise Price Range, upper limit	$ 100
Number Outstanding, Options Outstanding | shares	91,700
Weighted Average Remaining Contractual, Options Outstanding	6 years 8 months 9 days
Weighted Average Exercise Price, Options Outstanding	$ 29.17
Number Outstanding, Options Exercisable | shares	90,105
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	6 years 9 months 29 days
Weighted Average Exercise Price, Options Exercisable	$ 29.35
Exercise Price Range Three [Member]
Exercise Price Range, lower limit	100.01
Exercise Price Range, upper limit	$ 200
Number Outstanding, Options Outstanding | shares	92,847
Weighted Average Remaining Contractual, Options Outstanding	2 years 3 months 4 days
Weighted Average Exercise Price, Options Outstanding	$ 166.04
Number Outstanding, Options Exercisable | shares	92,847
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	2 years 3 months 4 days
Weighted Average Exercise Price, Options Exercisable	$ 166.04
Exercise Price Range Four [Member]
Exercise Price Range, lower limit	200.01
Exercise Price Range, upper limit	$ 277.50
Number Outstanding, Options Outstanding | shares	69,391
Weighted Average Remaining Contractual, Options Outstanding	1 year 1 month 2 days
Weighted Average Exercise Price, Options Outstanding	$ 210.79
Number Outstanding, Options Exercisable | shares	69,391
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	1 year 1 month 2 days
Weighted Average Exercise Price, Options Exercisable	$ 210.79

Share Based Compensation - Su_5

Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details)	6 Months Ended
	Apr. 30, 2021
Share-based Payment Arrangement [Abstract]
Expected Term	6 years
Expected Volatility	103.27%
Expected Dividends	0.00%
Risk Free Interest Rate	0.53%

Collaboration and Licensing A_2

Collaboration and Licensing Agreements (Details Narrative) - USD ($)	Apr. 30, 2020	Jan. 31, 2021	Dec. 31, 2020	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Revenue				$ 1,375,000	$ 250,000	$ 2,990,000	$ 253,000
Development, License and Supply Agreement [Member] | OS Therapies [Member]
Revenue	$ 25,000
Funding milestone payment	$ 2,337,500
Milestone Set forth in the License Agreement [Member] | OS Therapies LLC [Member]
Milestone achievement, description		The Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement.	The Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement.
Second Mile Stone License Agreement [Member] | OS Therapies [Member]
Due from affiliate				$ 1,375,000		$ 1,375,000

Leases (Details Narrative)

Leases (Details Narrative) - USD ($) $ in Thousands	Mar. 25, 2021	Apr. 30, 2021	Apr. 30, 2021
Operating lease expiration			Nov. 30, 2025
Early termination of lease payment			$ 1,000
Security deposit		$ 182	182
Net payment of lease termination fee			$ 817
Write off of the remaining right of use asset		4,500
write off of lease liability		5,600
Gain on termination of lease		$ 100
New Lease Agreement [Member]
Operating lease expiration	Mar. 31, 2022
Rent expense	$ 29
Lease description	The lease expires on March 25, 2022 and the Company has the option to renew the lease for one additional successive one year term upon six months written notice to the landlord. This new lease is accounted for as a short-term lease and the Company has elected to not recognize the right-of-use asset and lease liability.

Leases - Schedule of Lease Expe

Leases - Schedule of Lease Expenses (Details) - General and Administrative [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Operating lease cost	$ 1,011	$ 289	$ 1,301	$ 579
Short-term lease cost	16	85	16	169
Variable lease cost	61	129	159	270
Total lease expense	$ 1,088	$ 503	$ 1,476	$ 1,018

Leases - Schedule of Cash Flow

Leases - Schedule of Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Leases [Abstract]
Cash paid for operating lease liabilities	$ 1,039	$ 311	$ 1,363	$ 611

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Apr. 12, 2021	Mar. 31, 2021	Nov. 30, 2020	Apr. 30, 2021	Oct. 31, 2020
Common stock, par value				$ 0.001	$ 0.001
Number of warrants to purchase common stock				30,225,397	398,226
Common stock, authorized				170,000,000	170,000,000
Net proceeds from offering			$ 8,500
Amended and Restated Certificate of Incorporation [Member]
Common stock, par value	$ 0.001
Maximum [Member]
Warrants exercise price				$ 281.25	$ 281.25
Maximum [Member] | Amended and Restated Certificate of Incorporation [Member]
Common stock, authorized	300,000,000
Minimum [Member]
Warrants exercise price				$ 0.30	$ 0
Minimum [Member] | Amended and Restated Certificate of Incorporation [Member]
Common stock, authorized	170,000,000
Securities Purchase Agreements [Member] | Pre-Funded Warrants [Member]
Share price per share	$ 0.7911
Warrants exercise price	$ 0.70
ATM [Member]
Number of common stock shares sold		886,048
Proceeds from sale of common shares		$ 700
Public Offering [Member]
Number of common stock shares sold			30,666,665
Share price per share			$ 0.30
Pre-funded warrants to purchase common shares				7,671,937
Number of warrants to purchase common stock				10,754,932
Common stock, authorized				300,000,000
Proceeds from sale of common shares			$ 9,200
Net proceeds from offering				$ 3,800
Public Offering [Member] | Securities Purchase Agreements [Member]
Number of common stock shares sold	17,577,400
Common stock, par value	$ 0.001
Share price per share	$ 0.7921
Pre-funded warrants to purchase common shares	7,671,937
Ownership percentage	9.99%
Public Offering [Member] | Securities Purchase Agreements [Member] | Maximum [Member]
Number of warrants to purchase common stock	11,244,135
Private Placement [Member]
Number of warrants to purchase common stock			15,333,332
Warrants exercise price			$ 0.35
Private Placement [Member] | Purchase Agreement [Member]
Number of warrants to purchase common stock	14,005,202
Warrants exercise price	$ 0.70

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stockholders Equity (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Apr. 30, 2021	Jan. 31, 2021	Apr. 30, 2020	Jan. 31, 2020	Apr. 30, 2021	Apr. 30, 2020
Beginning balance	$ 37,575	$ 30,180	$ 35,437	$ 39,531	$ 30,180	$ 39,531
Stock-based compensation	$ 215	236	$ 210	242
Stock-based compensation, shares
Advaxis public offerings, net of offering costs	$ 13,683	8,550		9,628
Advaxis public offerings, net of offering costs, shares
Warrant exercises	$ 1,185	2,586		$ 2
Warrant exercises, shares
Issuance of shares to employees under ESPP Plan			$ 2	$ 2
Issuance of shares to employees under ESPP Plan, shares
Net Loss	$ (5,107)	$ (3,977)	$ (6,323)	$ (7,857)	(9,084)	(14,180)
Ending balance	47,551	37,575	(398,449)	35,437	47,551	(398,449)
Preferred Stock [Member]
Beginning balance
Beginning balance, shares
Stock-based compensation
Stock-based compensation, shares
Advaxis public offerings, net of offering costs
Advaxis public offerings, net of offering costs, shares
Warrant exercises
Warrant exercises, shares
Issuance of shares to employees under ESPP Plan
Issuance of shares to employees under ESPP Plan, shares
Net Loss
Ending balance
Ending balance, shares
Common Stock [Member]
Beginning balance	$ 116	$ 78	$ 60	$ 50	$ 78	$ 50
Beginning balance, shares	116,130,688	78,074,023	60,236,599	50,201,671	78,074,023	50,201,671
Stock-based compensation
Stock-based compensation, shares	5,888		5,651	2,957
Advaxis public offerings, net of offering costs	$ 19	$ 31		$ 10
Advaxis public offerings, net of offering costs, shares	18,463,448	30,666,665		10,000,000
Warrant exercises	$ 11	$ 7
Warrant exercises, shares	11,037,435	7,390,000	7,500	26,416
Issuance of shares to employees under ESPP Plan
Issuance of shares to employees under ESPP Plan, shares	1,000		2,694	5,555
Net Loss
Ending balance	$ 146	$ 116	$ 60	$ 60	$ 146	$ 60
Ending balance, shares	145,638,459	116,130,688	60,252,444	60,236,599	145,638,459	60,252,444
Additional Paid-In Capital [Member]
Beginning balance	$ 452,174	$ 440,840	$ 433,614	$ 423,750	$ 440,840	$ 423,750
Stock-based compensation	$ 215	236	$ 210	242
Stock-based compensation, shares
Advaxis public offerings, net of offering costs	$ 13,664	8,519		9,618
Advaxis public offerings, net of offering costs, shares
Warrant exercises	$ 1,174	2,579		2
Warrant exercises, shares
Issuance of shares to employees under ESPP Plan			$ 2	2
Issuance of shares to employees under ESPP Plan, shares
Net Loss
Ending balance	467,227	452,174	433,826	433,614	467,227	433,826
Accumulated Deficit [Member]
Beginning balance	(414,715)	(410,738)	(392,126)	(384,269)	(410,738)	(384,269)
Stock-based compensation
Stock-based compensation, shares
Advaxis public offerings, net of offering costs
Advaxis public offerings, net of offering costs, shares
Warrant exercises
Warrant exercises, shares
Issuance of shares to employees under ESPP Plan
Issuance of shares to employees under ESPP Plan, shares
Net Loss	$ (5,107)	$ (3,977)	$ (6,323)	(7,857)
Ending balance	$ (419,822)	$ (414,715)	$ (398,449)	$ (392,126)	$ (419,822)	$ (398,449)

Fair Value - Schedule of Fair V

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Apr. 30, 2021	Oct. 31, 2020
Common stock warrant liability, warrants exercisable	$ 4,931	$ 17
Through September 2024 [Member]
Common stock warrant liability, warrants exercisable	29	17
Through 5 Years [Member]
Common stock warrant liability, warrants exercisable	4,902
Fair Value, Inputs, Level 1 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 1 [Member] | Through September 2024 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 1 [Member] | Through April 2026 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 2 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 2 [Member] | Through September 2024 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 2 [Member] | Through April 2026 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 3 [Member]
Common stock warrant liability, warrants exercisable	4,931
Fair Value, Inputs, Level 3 [Member] | Through September 2024 [Member]
Common stock warrant liability, warrants exercisable	29	$ 17
Fair Value, Inputs, Level 3 [Member] | Through April 2026 [Member]
Common stock warrant liability, warrants exercisable	$ 4,902

Fair Value - Schedule of Fair_2

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) (Parenthetical) - $ / shares	Apr. 30, 2021	Oct. 31, 2020
Through September 2024 [Member]
Warrant exercise price per share	$ 0.30	$ 0.372
Through 5 Years [Member]
Warrant exercise price per share	$ 0.70

Fair Value - Schedule of Change

Fair Value - Schedule of Changes in Fair Value of Warrant Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Apr. 30, 2021	Jan. 31, 2021	Apr. 30, 2020	Jan. 31, 2020	Apr. 30, 2021
Beginning balance		$ 17			$ 17
Warrant exercises	$ 1,185	2,586		$ 2
Ending Balance	4,931				4,931
Warrant Liability [Member]
Beginning balance		$ 17			17
Warrants issued					5,882
Warrant exercises
Change in fair value					(968)
Ending Balance	$ 4,931				$ 4,931